Patent Publication Number: US-2022220523-A1

Title: Composition for producing glucosylated steviol glycoside including glucosyltransferase and method of producing glucosylated steviol glycoside using the same

Description:
TECHNICAL FIELD 
     The present disclosure relates to a composition for producing glucosylated steviol glycoside, the composition including glucosyltransferase; and a method of producing glucosylated steviol glycoside using the same. 
     BACKGROUND ART 
     As the World Health Organization (WHO) recommends lowering the amount of daily sugar intake due to concerns about disease (obesity) caused by sugar consumption, various policies aimed at reducing the amount of sugar intake are actively being discussed by the governments of developed countries. Therefore, as the need for developing various alternative sweeteners is increasing in the market, alternative sweeteners are continuously being developed and commercialized. As alternative sweeteners, these are the subject of continuous variation in the form of synthetic high-intensity sweeteners (e.g., Saccharin, Aspartame, Sucralose, etc.), synthetic sugar alcohols (e.g., Maltitol and Xylitol), and high-intensity sweeteners (e.g., Rebaudioside A and Liquorice). Nevertheless, due to concerns over the safety of synthetic sweeteners, customers&#39; need for natural sweeteners has been steadily increasing; however, because of limitations to peculiar flavor properties of natural sweeteners (i.e., off-smell and off-flavor), natural sweeteners cannot fully replace existing low-calorie and zero-calorie products based on synthetic sweeteners. 
     A natural high-intensity sweetener that has received considerable attention in recent years is  stevia  extracted from the leaves of  Stevia rebaudiana  Bertoni.  Stevia  is a natural material, the sweetness of which is 200 to 300 times that of sugar, and consists of Stevioside, Rebaudioside A, Rebaudioside B, Rebaudioside C, Rebaudioside D, Rebaudioside E, Rebaudioside M, etc. In addition,  stevia  has no calories and positive effects on blood glucose and insulin levels, and has been reported to have no adverse effects in the human body. However, although  stevia  has potential to be used as an alternative sweetener, it has limitations in application due to the disadvantage that it expresses strong bitter taste. 
     Methods for improving sweetness of  stevia  include a method of transferring a saccharide using an enzyme. As the method, a method of transferring 1 to 12 glucose molecules to a steviol glycoside using CGTase is widely used in the art (Korean Patent Application No. 10-1991-0020769). However, the method has a disadvantage in that the glucose structure transferred to the steviol glycoside is α-(1,4) and is all degraded by intestinal microorganisms, thereby increasing calories. 
     DISCLOSURE 
     Technical Problem 
     Under such circumstances, the present inventors have completed the present disclosure by confirming that an enzyme derived from  Lactobacillus mali  transfers glucose to steviol glycoside via an α-(1,6) bond to produce indigestible glucosylated steviol glycoside. 
     Technical Solution 
     An object of the present disclosure is to provide a composition for producing glucosylated steviol glycoside, the composition including glucosyltransferase including an amino acid sequence of SEQ ID NO: 1, a microorganism expressing the glucosyltransferase, or a culture of the microorganism. 
     Another object of the present disclosure is to provide a method of producing glucosylated steviol glycoside, the method including the step of contacting steviol glycoside with the glucosyltransferase including the amino acid sequence of SEQ ID NO: 1, the microorganism expressing the glucosyltransferase, or the culture of the microorganism. 
     Still another object of the present disclosure is to provide glucosylated steviol glycoside produced by the above production method. 
     Still another object of the present disclosure is to provide a sweetener composition including the glucosylated steviol glycoside. 
     Still another object of the present disclosure is to provide a composition for improving sweetness, the composition including the glucosyltransferase including the amino acid sequence of SEQ ID NO: 1, the microorganism expressing the glucosyltransferase, or the culture of the microorganism. 
     Still another object of the present disclosure is to provide a method of improving sweetness of steviol glycoside, the method including the step of converting steviol glycoside into glucosylated steviol glycoside using the glucosyltransferase including the amino acid sequence of SEQ ID NO: 1, the microorganism expressing the glucosyltransferase, or the culture of the microorganism. 
     Advantageous Effects 
     The composition of the present disclosure for producing glucosylated steviol glycoside and the method of the present disclosure for producing glucosylated steviol glycoside employ glucosyltransferase including an amino acid sequence of SEQ ID NO: 1, thereby specifically producing glucosylated steviol glycoside. 
     Additionally, since the glucosyltransferase has a high conversion rate of glucosylated steviol glycoside from steviol glycoside, it is possible to very efficiently produce glucosylated steviol glycoside. 
    
    
     
       BRIEF DESCRIPTION OF DRAWINGS 
         FIG. 1  shows SDS-PAGE results of proteins in four kinds of fractions purified from a culture of  Lactobacillus mali.    
         FIG. 2  shows HPLC results before reacting Rebaudioside A and sugar with a crude enzyme solution of  Lactobacillus mali.    
         FIG. 3  shows HPLC results after reacting Rebaudioside A and sugar with the crude enzyme solution of  Lactobacillus mali.    
         FIG. 4  shows HPLC results before reacting Stevioside and sugar with the crude enzyme solution of  Lactobacillus mali.    
         FIG. 5  shows HPLC results after reacting Stevioside and sugar with the crude enzyme solution of  Lactobacillus mali.    
         FIG. 6  shows HPLC results before reacting Rebaudioside A and sugar with an enzyme including an amino acid sequence of SEQ ID NO: 1. 
         FIG. 7  shows HPLC results after reacting Rebaudioside A and sugar with the enzyme including the amino acid sequence of SEQ ID NO: 1. 
     
    
    
     BEST MODE FOR CARRYING OUT THE INVENTION 
     Hereinbelow, the present disclosure will be described in detail. Meanwhile, each of the explanations and exemplary embodiments disclosed herein may be applied to other explanations and exemplary embodiments. That is, all combinations of various factors disclosed herein belong to the scope of the present disclosure. Furthermore, the scope of the present disclosure should not be limited by the specific disclosure provided hereinbelow. 
     In order to achieve the objects, an aspect of the present disclosure provides a composition for producing glucosylated steviol glycoside, the composition including glucosyltransferase including an amino acid sequence of SEQ ID NO: 1, a microorganism expressing the glucosyltransferase, or a culture of the microorganism. 
     As used herein, the “glucosyltransferase” refers to an enzyme that transfers glucose from a glucose donor to a glucose acceptor. 
     The glucosyltransferase may have a use for producing glucosylated steviol glycoside by transferring glucose from a glucose donor to steviol glycoside. 
     The glucosyltransferase may be an enzyme including the amino acid sequence of SEQ ID NO: 1. The enzyme including the amino acid sequence of SEQ ID NO: 1 may be used interchangeably with an enzyme having the amino acid sequence of SEQ ID NO: 1, an enzyme essentially consisting of the amino acid sequence of SEQ ID NO: 1, or an enzyme consisting of the amino acid sequence of SEQ ID NO: 1. 
     Further, although the glucosyltransferase in the present disclosure is defined as the enzyme including the amino acid sequence of SEQ ID NO: 1, it does not exclude a mutation that may occur by adding a meaningless sequence upstream or downstream the amino acid sequence of SEQ ID NO: 1, a naturally occurring mutation, or a silent mutation, and it is apparent to those skilled in the art that as long as a protein has activity identical to or corresponding to that of the enzyme including the amino acid sequence of SEQ ID NO: 1, essentially consisting of the amino acid sequence of SEQ ID NO: 1, or consisting of the amino acid sequence of SEQ ID NO: 1, it corresponds to the glucosyltransferase of the present disclosure. For specific example, the glucosyltransferase of the present disclosure may be a protein consisting of the amino acid sequence of SEQ ID NO: 1, or a protein consisting of an amino acid sequence having 80%, 90%, 95%, or 97% or more homology or identity thereto. Additionally, it is obvious that any protein having an amino acid sequence with deletion, modification, substitution, or addition in part of the sequence may also be included in the scope of the glucosyltransferase of the present disclosure, as long as the amino acid sequence has a homology or identity described above and exhibits efficacy corresponding to that of the enzyme. 
     That is, although described as “an enzyme or protein having an amino acid sequence of a particular SEQ ID NO” or “an enzyme or protein consisting of an amino acid sequence of a particular SEQ ID NO” in the present disclosure, it is obvious that any protein having an amino acid sequence with deletion, modification, substitution, or addition in part of the sequence may also be used in the present disclosure, as long as the protein may have an activity identical or corresponding to that of a polypeptide including the amino acid sequence of the corresponding SEQ ID NO. For example, it is obvious that any “polypeptide consisting of the amino acid sequence of SEQ ID NO: 1” may belong to “the polypeptide including the amino acid sequence of SEQ ID NO: 1”, as long as it has an activity identical or corresponding to that of the polypeptide including the amino acid sequence of SEQ ID NO: 1. 
     As used herein, the term “homology” or “identity” refers to a degree of matching with two given amino acid sequences or nucleotide sequences, and may be expressed as a percentage. The terms “homology” and “identity” may often be used interchangeably with each other. 
     The homology or identity of conserved polynucleotide or polypeptide sequences may be determined by standard alignment algorithms and may be used with a default gap penalty established by the program being used. Substantively, homologous or identical sequences may generally hybridize under moderate or high stringent conditions, along the entire length or at least about 50%, about 60%, about 70%, about 80%, or about 90% of the entire length of the sequences. Polynucleotides that contain degenerate codons instead of codons in the hybridizing polynucleotides are also considered. 
     Whether any two polynucleotide or polypeptide sequences have a homology, similarity, or identity may be determined using a known computer algorithm such as the “FASTA” program (e.g., Pearson et al., (1988)[Proc. Natl. Acad. Sci. USA 85]: 2444) using default parameters. Alternately, it may be determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453), which is performed in the Needleman program of the EMBOSS package ((EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later) (GCG program package (Devereux, J., et al., Nucleic Acids Research 12: 387 (1984)), BLASTP, BLASTN, FASTA (Atschul, [S.] [F.,] [ET AL, J MOLEC BIOL 215]: 403 (1990); Guide to Huge Computers, Martin J. Bishop, [ED.,] Academic Press, San Diego, 1994, and [CARILLO ETA/.](1988) SIAM J Applied Math 48: 1073). For example, the homology, similarity, or identity may be determined using BLAST or ClustalW of the National Center for Biotechnology Information. 
     The homology, similarity, or identity of polynucleotide or polypeptide sequences may be determined by comparing sequence information using, for example, the GAP computer program (e.g., Needleman et al., (1970), J Mol Biol. 48: 443), as published in Smith and Waterman, Adv. Appl. Math (1981) 2:482. In summary, the GAP program defines the homology, similarity, or identity as the value obtained by dividing the number of similarly aligned symbols (i.e., nucleotides or amino acids) by the total number of the symbols in the shorter of the two sequences. Default parameters for the GAP program may include (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non-identities) and the weighted comparison matrix of Gribskov et al (1986) Nucl. Acids Res. 14: 6745, as disclosed in Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation, pp. 353-358 (1979) (or EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap (or a gap opening penalty of 10 and a gap extension penalty of 0.5); and (3) no penalty for end gaps. 
     Further, whether any two polynucleotide or polypeptide sequences have a homology, similarity, or identity may be determined by comparing sequences by Southern hybridization experiments under defined stringent conditions, and the defined appropriate hybridization conditions may be within a range in the art and may be determined by a method well known to those skilled in the art (e.g., J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, N.Y., 1989; F. M. Ausubel et al., Current Protocols in Molecular Biology, John Wiley &amp; Sons, Inc., New York). 
     The glucosyltransferase including the amino acid sequence of SEQ ID NO: 1 may be an enzyme derived from the genus  Lactobacillus , and specifically, an enzyme derived from  Lactobacillus mali , but is not limited thereto. 
     The glucosyltransferase including the amino acid sequence of SEQ ID NO: 1 may have a conversion rate of 50% or more, specifically 60% or more, more specifically 70% or more, much more specifically 80% or more, and even much more specifically 90% or more from steviol glycoside into glucosylated steviol glycoside, but is not limited thereto. 
     The composition of the present disclosure for producing glucosylated steviol glycoside may include a microorganism expressing the glucosyltransferase including the amino acid sequence of SEQ ID NO: 1, or a culture of the microorganism. 
     The microorganism may be specifically a microorganism of the genus  Lactobacillus , and more specifically  Lactobacillus mali , but is not limited thereto, as long as it is a microorganism that may include or express the glucosyltransferase of the present disclosure. 
     Specifically, the culture may be a culture including the microorganism expressing the glucosyltransferase including the amino acid sequence of SEQ ID NO: 1, or a culture from which the microorganism is excluded. 
     The composition of the present disclosure for producing glucosylated steviol glycoside may further include steviol glycoside and a glucose donor. 
     The “steviol glycoside”, which is one of natural sweeteners, may be represented by Chemical Formula 1 below. 
     
       
         
         
             
             
         
       
     
     In Chemical Formula 1, to R 1 , hydrogen (H) may be bound, or 1 to 3 glucose molecules may be bound via a β-bond; and to R 2 , one molecule of glucose, xylose, or rhamnose may be bound via a β-bond, and 0 to 2 glucose molecules may be bound thereto via a β-bond, but they are not limited thereto. 
     The steviol glycoside may be one or more selected from the group consisting of Stevioside, Rubusoside, Dulcoside A, Rebaudioside A, Rebaudioside C, Rebaudioside D, Rebaudioside E, Rebaudioside F, and Rebaudioside M, but is not limited thereto. 
     The glucose donor may be any one of an oligomer of glucose, a polymer of glucose, or a cyclic form thereof which may be reacted in the presence of glucosyltransferase such that one or more glucose molecules may be transferred to the steviol glycoside, and specifically, it may be sugar, but is not limited thereto. 
     The “glucosylated steviol glycoside” may be in the form in which glucose is linked to steviol glycoside. 
     Specifically, the glucosylated steviol glycoside may be in the form in which glucose is linked to steviol glycoside via an α-(1,6) bond. 
     Specifically, the glucosylated steviol glycoside may be in the form in which glucose is linked via an α-(1,6) bond to glucose linked at 19-OH position of steviol glycoside. 
     Specifically, the glucosylated steviol glycoside may be in the form in which 1 to 3 glucose molecules are linked to steviol glycoside. 
     The composition of the present disclosure for producing glucosylated steviol glycoside may further include a cofactor capable of advantageously transferring glucose to steviol glycosides or capable of enhancing stability of the composition, but is not limited thereto. Examples of the cofactor may include metal ions, metal salts, excipients, preservatives, etc., but are not limited thereto. 
     To achieve the above object, another aspect of the present disclosure provides a method of producing glucosylated steviol glycoside, the method including the step of contacting steviol glycoside with the glucosyltransferase including the amino acid sequence of SEQ ID NO: 1, the microorganism expressing the glucosyltransferase, or the culture of the microorganism. 
     The “glucosyltransferase including the amino acid sequence of SEQ ID NO: 1”, “microorganism”, “culture”, and “glucosylated steviol glycoside” are the same as described above. 
     The method of the present disclosure for producing glucosylated steviol glycoside may include the step of reacting a glucose donor (e.g., sugar) and steviol glycoside in the presence of the glucosyltransferase including the amino acid sequence of SEQ ID NO: 1, the microorganism expressing the glucosyltransferase, or the culture of the microorganism. In this regard, the “glucose donor” and “steviol glycoside” are the same as described above. 
     The step of reacting the glucose donor and steviol glycoside may be carried out at pH of 1 to 10, specifically at pH of 2 to 9, more specifically at pH of 3 to 8, and much more specifically at pH of 5 to 6, but is not limited thereto. 
     The step of reacting the glucose donor and steviol glycoside may be carried out at 1° C. to 80° C., specifically at 5° C. to 70° C., more specifically at 25° C. to 50° C., and much more specifically at 35° C. to 45° C., but is not limited thereto. 
     Further, the step of reacting the glucose donor and steviol glycoside may be carried out at pH of 1 to 10, pH of 2 to 9, pH of 3 to 8, or pH of 5 to 6, and at 1° C. to 80° C., 5° C. to 70° C., 25° C. to 50° C., or 35° C. to 45° C., but is not limited thereto. 
     The method of the present disclosure for producing glucosylated steviol glycoside may further include the step of recovering glucosylated steviol glycoside. The recovery may employ various methods known in the art, for example, filtration, size-exclusion chromatography, ion-exchange chromatography, crystallization, HPLC, etc., but is not limited thereto. Further, the recovery step may include a purification process. 
     To achieve the above object, still another aspect of the present disclosure provides glucosylated steviol glycoside produced by the method of the present disclosure for producing glucosylated steviol glycoside. 
     The “glucosylated steviol glycoside” is the same as described above. 
     Specifically, the glucosylated steviol glycoside may be one or more selected from the group consisting of glucosylated Stevioside, glucosylated Rubusoside, glucosylated Dulcoside A, glucosylated Rebaudioside A, glucosylated Rebaudioside C, glucosylated Rebaudioside D, glucosylated Rebaudioside E, glucosylated Rebaudioside F, and glucosylated Rebaudioside M, but is not limited thereto. 
     To achieve the above object, still another aspect of the present disclosure provides a sweetener composition including the glucosylated steviol glycoside of the present disclosure. 
     The sweetener composition of the present disclosure may have an improved bitter taste and improved solubility, as compared with a sweetener composition including steviol glycoside. 
     The improved bitter taste may be a reduced bitter taste. 
     The improved solubility may be increased solubility. 
     To achieve the above object, still another aspect of the present disclosure provides a composition for improving sweetness of steviol glycoside, the composition including the glucosyltransferase including the amino acid sequence of SEQ ID NO: 1, the microorganism expressing the glucosyltransferase, or the culture of the microorganism. 
     The “glucosyltransferase including the amino acid sequence of SEQ ID NO: 1”, “microorganism”, “culture”, and “steviol glycoside” are the same as described above. 
     The sweetness improvement may be bitter taste improvement due to reduced bitter taste. 
     To achieve the above object, still another aspect of the present disclosure provides a method of improving sweetness of steviol glycoside, the method including the step of converting steviol glycoside into glucosylated steviol glycoside using the glucosyltransferase including the amino acid sequence of SEQ ID NO: 1, the microorganism expressing the glucosyltransferase, or the culture of the microorganism. 
     The “glucosyltransferase including the amino acid sequence of SEQ ID NO: 1”, “microorganism”, “culture”, “steviol glycoside”, and “glucosylated steviol glycoside” are the same as described above. 
     The converting step may be carried out at pH of 1 to 10, specifically at pH of 2 to 9, more specifically at pH of 3 to 8, and much more specifically at pH of 5 to 6, but is not limited thereto. 
     The converting step may be carried out at 1° C. to 80° C., specifically at 5° C. to 70° C., more specifically at 25° C. to 50° C., and much more specifically at 35° C. to 45° C., but is not limited thereto. 
     Further, the converting step may be carried out at pH of 1 to 10, pH of 2 to 9, pH of 3 to 8, or pH of 5 to 6, and at 1° C. to 80° C., 5° C. to 70° C., 25° C. to 50° C., or 35° C. to 45° C., but is not limited thereto. 
     The sweetness improvement may be bitter taste improvement due to reduced bitter taste. 
     DETAILED DESCRIPTION OF THE INVENTION 
     Hereinafter, the present disclosure will be described in more detail with reference to Examples and Experimental Examples. However, these Examples and Experimental Examples are only for illustrating the present disclosure, and the scope of the present disclosure is not intended to be limited by these Examples and Experimental Examples. 
     Example 1: Purification of Enzyme 
     A test tube was filled with 5 mL of MRS broth (BD Difco), and then  Lactobacillus mali  was seeded thereto, followed by incubation at 30° C. and 180 rpm for 15 hours. 
     Thereafter, a 250 mL flask was filled with 100 mL of MRS broth, and then the culture broth was seeded thereto at a concentration of 5% (v/v), followed by incubation at 30° C. and 180 rpm for 15 hours. 
     Thereafter, a 3 L fermentor was filled with 1 L of modified MRS broth, and then the culture broth was seeded thereto at a concentration of 5% (v/v), followed by incubation at 30° C. and 300 rpm for 24 hours. At this time, a composition of the modified MRS broth is the same as in Table 1 below. 
     
       
         
           
               
               
               
               
               
             
               
                   
                 TABLE 1 
               
               
                   
                   
               
               
                   
                 Composition 
                 Unit (g/L) 
                 Content 
                 Manufacturer 
               
               
                   
                   
               
             
            
               
                   
               
            
           
           
               
               
               
               
               
            
               
                   
                 Sucrose 
                 g 
                 20 
                 SIGMA 
               
               
                   
                 Polypeptone 
                 g 
                 10 
                 DAEJUNG 
               
               
                   
                 Yeast extract 
                 g 
                 5 
                 BD Difco 
               
               
                   
                 Beef extract 
                 g 
                 10 
                 BD Difco 
               
               
                   
                 Ammonium citrate 
                 g 
                 2 
                 DAEJUNG 
               
               
                   
                 Sodium acetate 
                 g 
                 5 
                 DAEJUNG 
               
               
                   
                 K 2 HPO 4   
                 g 
                 2 
                 DAEJUNG 
               
               
                   
                 MgSO 4 —7H 2 O 
                 g 
                 0.1 
                 JUNSEI 
               
               
                   
                 MnSO 4 —H 2 O 
                 g 
                 0.05 
                 JUNSEI 
               
               
                   
                 Tween 80 
                 g 
                 1 
                 DAEJUNG 
               
               
                   
                   
               
            
           
         
       
     
     The culture broth was centrifuged at 13,000 rpm for 15 minutes to recover a supernatant. The supernatant was subjected to dialysis using a 20 mM Tris-HCl, pH 7.4 buffer to perform protein purification. 
     In primary purification, anion-exchange chromatography was used, and Hitrap™ DEAE FF (GE healthcare) column was used. The sample was loaded onto the column at a flow rate of 1 mL/min, followed by elution using a 20 mM Tris-HCl, pH 7.4 buffer containing 1 M NaCl. 
     In secondary purification, gel filtration chromatography was used, and Hiload™ 16/60 Superdex 200 pg (GE healthcare) column was used. Purification was carried out using a 20 mM Tris-HCl buffer containing 150 mM NaCl. 
     From the above purification, four kinds of fractions were obtained, and SDS-PAGE results of the respective fractions are shown in  FIG. 1 . 
     Example 2: Examination of Activity of Enzyme 
     To confirm the presence of the desired enzyme, sugar hydrolysis activity of each fraction was examined by a reducing sugar determination method (DNS method). 
     A 200 mM sugar solution and each fraction were mixed at a ratio of 1:1 in a 50 mM sodium acetate buffer, and allowed to react in a water bath at 40° C. for 10 minutes, followed by inactivation at 100° C. A DNS reagent was added thereto at a ratio of 1:3, and then mixed and allowed to react at 100° C. for 5 minutes, and then DNS reaction was immediately stopped on ice. Thereafter, optical density (OD) of the DNS reagent was measured at 575 nm, and the activity was confirmed from a constructed fructose standard curve. At this time, 1 unit is defined by the amount (mL) of an enzyme that produces 1 μmole of fructose per 1 minute. 
     As a result, it was confirmed that a 75 kDa protein of Fraction No. 2 had sugar hydrolysis activity. 
     Example 3: Identification of Enzyme 
     The 75 kDa protein was identified by LC-MS. 
     Example 3-1: Pretreatment of Sample (in Gel Trypsin Digestion) 
     For protein identification using mass spectrometry (MS), fragmentation of the protein to be analyzed into peptides is needed. 
     Therefore, the gel corresponding to 75 kDa of fraction #2 of  FIG. 1  was cut, and then a 50% CH 3 CN(H 2 O) solvent was added to the in-gel piece sample, and destained by reacting for 15 minutes. Thereafter, 2 μL of 1 M dithiothreitol (DTT, GE) dissolved in a 50 mM ammonium bicarbonate (ABC, SIGMA) buffer was added, and stored at room temperature for 1 hour. Then, 4 μL of 1 M iodoacetamide (IAA, SIGMA) dissolved in a 50 mM ammonium bicarbonate (ABC, SIGMA) buffer was added, and stored in the dark at room temperature for 1 hour. 1 μg of a trypsin solution (Sequencing-grade modified porcine trypsin, Thermofisher, Madison, Wis., USA) was added to the destained in-gel piece sample, and allowed to react at 37° C. for 16 hours. 200 μL of a 50% CH 3 CN(H 2 O) solvent was added to recover the hydrolyzed peptides through gel dehydration, which were then dried using a SpeedDry vacuum concentrator. In order to remove salts and other impurities, desalting was carried out using C18 Ziptip (Millipore). 
     Example 3-2: Liquid Chromatography-Mass Spectrometry (LC-MS) 
     Liquid chromatography-mass spectrometry was performed using Ultimate 3000 RS UHPLC, Q-Exactive Orbitrap (Thermo Scientific) mass spectrometer, and analysis conditions are as follows: 
     (1) Chromatography: Thermo (Dionex) UHPLC Ultimate 3000 
     (2) Column: Acclaim prepMap™ RSLC 50 μm×15 cm, nanoviper C18, 2 μm, 100 A 
     (3) Solvent: A=distilled water (containing 0.1% formic acid), B=acetonitrile (containing 0.1% formic acid) 
     (4) Elution conditions 
     
       
         
           
               
               
               
             
               
                 TABLE 2 
               
               
                   
               
               
                 Time (min) 
                 A (%) 
                 B (%) 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 0 
                 95 
                 5 
               
               
                 5 
                 95 
                 5 
               
               
                 63 
                 70 
                 30 
               
               
                 68 
                 50 
                 50 
               
               
                 70 
                 20 
                 80 
               
               
                 73 
                 20 
                 80 
               
               
                 75 
                 95 
                 5 
               
               
                 88 
                 95 
                 5 
               
               
                 89 
                 95 
                 5 
               
               
                   
               
            
           
         
       
     
     (5) Flow rate: 0.2 μL/min 
     (6) Sample injection: 1 μL 
     Thereafter, amino acid sequences were examined by de novo peptide sequencing, and at this time, Proteome Discoverer 2.1 (Thermo) was used as an analysis program. 
     The thus-confirmed amino acid sequence was SEQ ID NO: 1. 
     Example 4: Examination of Activity of Crude Enzyme Solution of Transferring Glucose to Steviol Glycoside 
     6% Rebaudioside A (purecircle) or 6% Stevioside (carbosynth), and 6% white sugar (CJ CheilJedang) were dissolved in a 50 mM sodium acetate buffer (pH 5.0), and then the  Lactobacillus mali  crude enzyme solution including the enzyme including the amino acid sequence of SEQ ID NO: 1 was added thereto, and allowed to react at 40° C. for 24 hours. Thereafter, whether glucosylated Rebaudioside A or glucosylated Stevioside was produced was confirmed by HPLC, and the results are shown in  FIGS. 2 to 5 . Meanwhile, HPLC analysis conditions are as follows: 
     
       
         
           
               
               
             
               
                 TABLE 3 
               
               
                   
               
             
            
               
                 Mobile phase 
                 Acetonitrile (30%):Distilled water (70%) 
               
               
                 Column 
                 250 × 4.6 mm Capcell pak C18 MG II (Shiseido) 
               
            
           
           
               
               
               
            
               
                 Flow rate 
                 0.6 
                 mL/min 
               
               
                 Temperature 
                 30° 
                 C. 
               
               
                 Injection amount 
                 20 
                 μL 
               
               
                 Detector 
                 DAD 
                 (210 nm) 
               
               
                   
               
            
           
         
       
     
       FIGS. 2 and 4  show HPLC analysis results before the enzyme reaction, and  FIGS. 3 and 5  show HPLC analysis results after the enzyme reaction. 
     Comparison of  FIGS. 2 and 3  showed that Rebaudioside A was converted into glucosylated Rebaudioside A (Rebaudioside A-G1) by the enzyme reaction. At this time, it was confirmed that the conversion rate was about 90%. 
     Further, comparison of  FIGS. 4 and 5  showed that Stevioside was converted into glucosylated Stevioside (Stevidoside-G1) by the enzyme reaction. At this time, it was confirmed that the conversion rate was about 90%. 
     Meanwhile, it was confirmed by NMR that the glucosylated Stevioside (Stevidoside-G1) and the glucosylated Rebaudioside A (Rebaudioside A-G1) were produced by transferring one glucose molecule via an α-(1,6) bond to glucose linked at 19-OH position of Stevioside and Rebaudioside A, respectively. 
     Example 5: Examination of Activity of Enzyme Including Amino Acid Sequence of SEQ ID NO: 1 of Transferring Glucose to Steviol Glycoside 
     The activity of the enzyme including the amino acid sequence of SEQ ID NO: 1, which was confirmed in Example 3, was examined. Specifically, it was examined whether the enzyme has activity of transferring glucose to steviol glycoside. 
     Example 5-1: Preparation of Microorganism Including Enzyme and Purification of Enzyme 
     A polynucleotide encoding the amino acid sequence of SEQ ID NO: 1 was prepared by a polynucleotide synthesis method (Bioneer Corp.), and the obtained polynucleotide was inserted into a pBT7-N-His vector, which was then transformed into  E. coli  BL21(DE3). The transformed  E. coli  was smeared on a plate medium containing ampicillin to obtain a recombinant strain (microorganism). 
     Meanwhile, the microorganism was deposited at the Korean Culture Center of Microorganisms, which is an international depositary authority under the Budapest Treaty, on Jun. 11, 2019, as Accession No. KCCM12561P. 
     The recombinant  E. coli  strain was seeded in 5 mL of an LB medium containing ampicillin, and seed culture was carried out at 37° C. until optical density at 600 nm reached 2.0. The seed culture broth was added to 500 mL of an LB medium containing ampicillin, and main culture was carried out. Thereafter, when optical density at 600 nm reached 0.4, 0.1 mM isopropyl β-D-thiogalactopyranoside (IPTG) was added to induce mass-expression of the enzyme including the amino acid sequence of SEQ ID NO: 1. During the process, an agitation speed was 180 rpm, and culture temperature was maintained at 37° C. After IPTG addition, the agitation speed was 120 rpm, and culture temperature was maintained at 16° C. 
     The culture broth was centrifuged at 10,000×g at 4° C. for 20 minutes to obtain a cell pellet. A 50 mM tris-HCl buffer solution was added to the pellet, and re-suspended as a cell solution. The cell solution was sonicated using a sonicator. The cell lysate was centrifuged at 13,000×g at 4° C. for 20 minutes to collect a supernatant only. Thereafter, the enzyme was purified using a Ni-NTA superflow column. 
     Example 5-2: Examination of Enzyme Activity 
     6% Rebaudioside A (purecircle) and 6% white sugar (CJ CheilJedang) were dissolved in a 50 mM sodium acetate buffer (pH 5.0), and then the enzyme including the amino acid sequence of SEQ ID NO: 1, which was obtained in Example 5-1, was added thereto, and allowed to react at 40° C. for 24 hours. Thereafter, whether glucosylated Rebaudioside A was produced was confirmed by HPLC, and the results are shown in  FIGS. 6 and 7 . 
       FIG. 6  shows HPLC analysis results before the enzyme reaction, and  FIG. 7  shows HPLC analysis results after the enzyme reaction. 
     Comparison of  FIGS. 6 and 7  showed that Rebaudioside A was converted into glucosylated Rebaudioside A (Rebaudioside A-G1) by the enzyme reaction. At this time, it was confirmed that the conversion rate was about 90%. 
     Meanwhile, it was confirmed by NMR that the glucosylated Rebaudioside A (Rebaudioside A-G1) was produced by transferring one glucose molecule via an α-(1,6) bond to glucose linked at 19-OH position of Rebaudioside A. 
     That is, it was confirmed that the enzyme including the amino acid sequence of SEQ ID NO: 1 had activity identical to that of the crude enzyme solution of  Lactobacillus mali  of Example 4. 
     Example 6: Evaluation of Solubility of Glucosylated Steviol Glycoside 
     The solubility of steviol glycoside and glucosylated steviol glycoside was measured. 
     Specifically, the solubility of Rebaudioside A (RA), Stevioside (STV), glucosylated Rebaudioside A (RA-Glu) of Example 4, and glucosylated Stevioside (STV-Glu) of Example 4 was measured, respectively. 
     Each 6 g of Rebaudioside A, Stevioside, glucosylated Rebaudioside A, and glucosylated Stevioside was mixed with 10 mL, and then dissolved by sonication at 50° C. for 60 minutes. The resultant was incubated for 1 week in a water bath at 5° C., 15° C., 25° C., 35° C., 45° C., or 55° C. Thereafter, the resulting solution was centrifuged at 12,000 rpm for 10 minutes, and 1 mL of the supernatant was collected and dried in an oven at 105° C. to measure the solubility, which is shown in Table 4. 
     
       
         
           
               
               
               
             
               
                 TABLE 4 
               
             
            
               
                   
               
               
                 Temperature 
                 Solubility (%) 
                   
               
            
           
           
               
               
               
               
               
            
               
                 (° C.) 
                 STV 
                 RA 
                 STV-Glu 
                 RA-Glu 
               
               
                   
               
            
           
           
               
               
               
               
               
            
               
                 5 
                 6.3 
                 1.1 
                 40 ↑ 
                 40 ↑ 
               
               
                 15 
                 6.2 
                 0.6 
                 40 ↑ 
                 40 ↑ 
               
               
                 25 
                 5.3 
                 0.3 
                 40 ↑ 
                 40 ↑ 
               
               
                 35 
                 9.2 
                 0.5 
                 40 ↑ 
                 40 ↑ 
               
               
                 45 
                 13.7 
                 1.1 
                 40 ↑ 
                 40 ↑ 
               
               
                 55 
                 39.7 
                 1.6 
                 40 ↑ 
                 40 ↑ 
               
               
                   
               
            
           
         
       
     
     According to the results of Table 4, it can be seen that the glucosylated Stevioside and the glucosylated Rebaudioside A showed remarkably increased solubility, as compared with Stevioside and Rebaudioside A, respectively. 
     Example 7: Evaluation of Sweetness and Quality of Sweetness of α-(1,6) Glucosylated Rebaudioside A 
     The known material (i.e., α-(1,4) glucosylated Rebaudioside A) and the α-(1,6) glucosylated Rebaudioside A of Example 4 were independently dissolved in water and provided to panels for evaluation of actual sweetness and quality of sweetness. The results are shown in Table 5 below. 
     
       
         
           
               
               
               
             
               
                 TABLE 5 
               
               
                   
               
               
                   
                 Actual 
                   
               
               
                 Sample 
                 Sweetness 
                 Evaluation of Quality of Sweetness 
               
               
                   
               
             
            
               
                 α-(1,4) glucosylated 
                 19 
                 Bitter taste is stronger than sweet taste, 
               
               
                 Rebaudioside A 
                   
                 has greasy taste like starch syrup. 
               
               
                   
                   
                 Weak off-smell compared to α-(1,6) 
               
               
                   
                   
                 glucosylated Rebaudioside A, but 
               
               
                   
                   
                 strong off-flavor. 
               
               
                 α-(1,6) glucosylated 
                 26 
                 Gives sweet taste in the beginning, has 
               
               
                 Rebaudioside A 
                   
                 a bit of bitter taste, but has clean taste. 
               
               
                   
                   
                 Has off-smell (alcohol smell, etc.). 
               
               
                   
               
            
           
         
       
     
     As shown in Table 5, it was confirmed that the α-(1,6) glucosylated Rebaudioside A showed high sweetness, as compared with the α-(1,4) glucosylated Rebaudioside A, and also had better quality of sweetness. 
     Based on the above description, it will be understood by those skilled in the art that the present disclosure may be implemented in a different specific form without changing the technical spirit or essential characteristics thereof. Therefore, it should be understood that the above embodiment is not limitative, but illustrative in all aspects. The scope of the disclosure is defined by the appended claims rather than by the description preceding them, and therefore all changes and modifications that fall within metes and bounds of the claims, or equivalents of such metes and bounds are therefore intended to be embraced by the claims.